GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eloxx Pharmaceuticals Inc (OTCPK:ELOX) » Definitions » Total Current Liabilities

Eloxx Pharmaceuticals (Eloxx Pharmaceuticals) Total Current Liabilities : $23.47 Mil (As of Sep. 2023)


View and export this data going back to 1998. Start your Free Trial

What is Eloxx Pharmaceuticals Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Eloxx Pharmaceuticals's total current liabilities for the quarter that ended in Sep. 2023 was $23.47

Eloxx Pharmaceuticals Total Current Liabilities Historical Data

The historical data trend for Eloxx Pharmaceuticals's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eloxx Pharmaceuticals Total Current Liabilities Chart

Eloxx Pharmaceuticals Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.81 11.81 9.84 9.96 23.09

Eloxx Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.68 23.09 19.46 21.25 23.47

Eloxx Pharmaceuticals Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Eloxx Pharmaceuticals's Total Current Liabilities for the fiscal year that ended in Dec. 2022 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=5.819+4.692
+Other Current Liabilities+Current Deferred Liabilities
=0.045000000000002+12.535
=23.09

Eloxx Pharmaceuticals's Total Current Liabilities for the quarter that ended in Sep. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=5.576+3.134
+Other Current Liabilities+Current Deferred Liabilities
=1.79+12.966
=23.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Eloxx Pharmaceuticals Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Eloxx Pharmaceuticals's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Eloxx Pharmaceuticals (Eloxx Pharmaceuticals) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eloxx Pharmaceuticals Inc (OTCPK:ELOX) » Definitions » Total Current Liabilities
Comparable Companies
ARDS MBIO GMDAQ CWBR INM XCUR CNSP SEEL FNCH APVO OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
N/A
Address
480 Arsenal Way, Watertown, MA, USA, 02472
Website
https://www.eloxxpharma.com
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in the science of ribosome modulation, leveraging both its ZM chemistry technology platform and its library of novel aminoglycosides to develop novel oral small molecule Ribosome Modulating Agents (RMAs) and Eukaryotic Ribosome Selective Glycosides (ERSGs), for the treatment of rare and ultra-rare genetic diseases where patients have point nonsense genetic mutations that result in premature stop codons and less than full-length proteins. The ELX-02, the company's investigational drug product candidate, is a small molecule designed to restore the production of full-length functional proteins.
Executives
Sumit Aggarwal director, officer: PRESIDENT AND CEO 480 ARSENAL WAY, WATERTOWN MA 02472
Vijay Modur officer: HEAD OF R&D C/O ELOXX PHARMACEUTICALS, INC., 950 WINTER ST., WALTHAM MA 02451
Lindsay Androski director C/O ELOXX PHARMACEUTICALS, INC., 480 ARSENAL WAY, WATERTOWN MA 02472
Gadi Veinrib director 12 MIKHA'EL NE'EMAN ST, TEL AVIV-YAFO L3 6958101
Steven D Rubin director OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
Jasbir Seehra director C/O ELOXX PHARMACEUTICALS, INC., 950 WINTER STREET, WALTHAM MA 02451
Zafrira Avnur director 210 ALLANDALE ST #1B, CHESTNUT HILL MA 02467
Alan Edmund Walts director 197 8TH STREET, APARTMENT 804, CHARLESTOWN MA 02129
Daniel E. Geffken officer: Chief Financial Officer DAMONMILL SQUARE, SUITE 6A, CONCORD MA 01742
Pontifax Iv Gp L.p. 10 percent owner 14 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 46140
Pontifax Management 4 G.p. (2015) Ltd. 10 percent owner 14 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 46140
Pontifax (israel) Iv, L.p. 10 percent owner 14 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 46140
Pontifax (china) Iv L.p. 10 percent owner 14 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 46140
Pontifax (cayman) Iv L.p. 10 percent owner 4 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 46140
Ran Nussbaum director C/O KITE PHARMA, INC., 2225 COLORADO AVENUE, SANTA MONICA CA 90404

Eloxx Pharmaceuticals (Eloxx Pharmaceuticals) Headlines

From GuruFocus

Eloxx Pharmaceuticals Reports Second Quarter 2022 Financial and Operating Results and Provides Business Update

By PurpleRose PurpleRose • 08-15-2022

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis (CF) Patients

By sperokesalga sperokesalga • 06-14-2023

Eloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business Update

By Marketwired • 08-14-2023

Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria

By Marketwired • 10-09-2023

Eloxx Pharmaceuticals Reports Drug Response in All Patients Treated with�ELX-02 in Phase 2 Clinical Study for Alport Syndrome

By Marketwired • 08-14-2023

Eloxx Pharmaceuticals Reports First Quarter 2022 Financial and Operating Results and Provides Business Update

By GuruFocusNews GuruFocusNews • 06-29-2022

Eloxx Pharmaceuticals Reports Third Quarter 2022 Financial and Operating Results and Provides Business Update

By Value_Insider Value_Insider • 11-10-2022

Eloxx Pharmaceuticals Reports First Quarter 2022 Financial and Operating Results and Provides Business Update

By GuruFocusNews GuruFocusNews • 07-09-2022

Eloxx Pharmaceuticals Key Opinion Leader Event Highlights Significant Unmet Need in Treatment of Alport Syndrome Patients with Nonsense Mutations and Additional Positive Results from Phase 2 Clinical Study Evaluating ELX-02

By Marketwired • 06-28-2023

Eloxx Pharmaceuticals Announces First Patients Enrolled in Phase 2 Clinical Study Evaluating ELX-02 for the Treatment of Alport Syndrome

By Stock market mentor Stock market mentor • 01-25-2023